CARGO Therapeutics Announces Phase 1 Clinical Study of Firi-cel CAR T-Cell Therapy Published in The Lancet
July 10, 2024 08:00 ET
|
Cargo Therapeutics, Inc.
CARGO Therapeutics Announces Phase 1 Clinical Study of Firi-cel CAR T-Cell Therapy Published in The Lancet
CARGO Therapeutics to Participate in Upcoming Investor Conferences
May 28, 2024 08:05 ET
|
Cargo Therapeutics, Inc.
CARGO Therapeutics to Participate in Upcoming Investor Conferences
CARGO Therapeutics Announces Pricing of Initial Public Offering
November 09, 2023 20:07 ET
|
Cargo Therapeutics, Inc.
CARGO Therapeutics Announce Pricing of IPO
Sorrento Receives FDA Clearance to Start Clinical Trial of Anti-CD47 Antibody, Discovered from Fully Human G-MAB Library, for Treatment of Multiple Malignancies
March 02, 2021 09:00 ET
|
Sorrento Therapeutics, Inc.
Internally developed fully human anti-CD47 antibody (STI-6643) cleared for basket trial;No complicated titration or priming dose of the antibody is required to reduce toxicity;This study will be...